Amycretin vs Mazdutide
Amycretin and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Amycretin
Dossier overview
Mazdutide
Dossier overview
What the evidence actually compares
Amycretin is a single molecule designed to activate GLP-1 and amylin receptors. Mazdutide instead activates GLP-1 and glucagon receptors. Amycretin is not the separate cagrilintide-plus-semaglutide combination called CagriSema.
Published randomized early-phase amycretin studies include an oral formulation trial and a subcutaneous phase 1b/2a trial in adults with overweight or obesity. These establish early clinical weight and tolerability observations for their particular formulations and follow-up periods; they are not a published head-to-head comparison with mazdutide or a substitute for phase 3 outcome results. Oral amycretin, PMID 40550229 · Subcutaneous amycretin, PMID 40550231
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | Amycretin | Mazdutide |
|---|---|---|
| Mechanism | Amycretin is a single molecule designed to activate GLP-1 and amylin receptors. Mazdutide instead activates GLP-1 and glucagon receptors. Amycretin is not the separate cagrilintide-plus-semaglutide combination called CagriSema. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | Published oral and subcutaneous early-phase studies | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited Amycretin sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
Mazdutide’s cited GLORY phase 3 trials and amycretin’s cited early-phase trials differ in phase, geography, population and endpoint timing. Their published percentages should not be ranked across trials.
Amycretin remained investigational in the reviewed sources; no FDA approval was verified for it or for mazdutide. Innovent separately reports specified Chinese mazdutide approvals. The source for the Amycretin evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.